553 related articles for article (PubMed ID: 28404863)
41. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.
Kurnellas M; Mitra A; Schwabe T; Paul R; Arrant AE; Roberson ED; Ward M; Yeh F; Long H; Rosenthal A
J Transl Med; 2023 Jun; 21(1):387. PubMed ID: 37322482
[TBL] [Abstract][Full Text] [Related]
42. Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency.
Frew J; Baradaran-Heravi A; Balgi AD; Wu X; Yan TD; Arns S; Shidmoossavee FS; Tan J; Jaquith JB; Jansen-West KR; Lynn FC; Gao FB; Petrucelli L; Feldman HH; Mackenzie IR; Roberge M; Nygaard HB
Mol Neurodegener; 2020 Mar; 15(1):21. PubMed ID: 32178712
[TBL] [Abstract][Full Text] [Related]
43. Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutations.
Davis SE; Cook AK; Hall JA; Voskobiynyk Y; Carullo NV; Boyle NR; Hakim AR; Anderson KM; Hobdy KP; Pugh DA; Murchison CF; McMeekin LJ; Simmons M; Margolies KA; Cowell RM; Nana AL; Spina S; Grinberg LT; Miller BL; Seeley WW; Arrant AE
Acta Neuropathol Commun; 2023 Apr; 11(1):70. PubMed ID: 37118844
[TBL] [Abstract][Full Text] [Related]
44. Progranulin haploinsufficiency mediates cytoplasmic TDP-43 aggregation with lysosomal abnormalities in human microglia.
Sung W; Noh MY; Nahm M; Kim YS; Ki CS; Kim YE; Kim HJ; Kim SH
J Neuroinflammation; 2024 Feb; 21(1):47. PubMed ID: 38347588
[TBL] [Abstract][Full Text] [Related]
45. Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia.
Simon MJ; Logan T; DeVos SL; Di Paolo G
Trends Cell Biol; 2023 Apr; 33(4):324-339. PubMed ID: 36244875
[TBL] [Abstract][Full Text] [Related]
46. Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia.
Arrant AE; Filiano AJ; Unger DE; Young AH; Roberson ED
Brain; 2017 May; 140(5):1447-1465. PubMed ID: 28379303
[TBL] [Abstract][Full Text] [Related]
47. Progranulin as a therapeutic target in neurodegenerative diseases.
Rhinn H; Tatton N; McCaughey S; Kurnellas M; Rosenthal A
Trends Pharmacol Sci; 2022 Aug; 43(8):641-652. PubMed ID: 35039149
[TBL] [Abstract][Full Text] [Related]
48. Exploring dementia and neuronal ceroid lipofuscinosis genes in 100 FTD-like patients from 6 towns and rural villages on the Adriatic Sea cost of Apulia.
Sassi C; Capozzo R; Hammer M; Zecca C; Federoff M; Blauwendraat C; Bernstein N; Ding J; Gibbs JR; Price T; Singleton A; Logroscino G
Sci Rep; 2021 Mar; 11(1):6353. PubMed ID: 33737586
[TBL] [Abstract][Full Text] [Related]
49. Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD.
Wu Y; Shao W; Todd TW; Tong J; Yue M; Koga S; Castanedes-Casey M; Librero AL; Lee CW; Mackenzie IR; Dickson DW; Zhang YJ; Petrucelli L; Prudencio M
Cell Rep; 2021 Aug; 36(8):109581. PubMed ID: 34433069
[TBL] [Abstract][Full Text] [Related]
50. Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation.
Chang MC; Srinivasan K; Friedman BA; Suto E; Modrusan Z; Lee WP; Kaminker JS; Hansen DV; Sheng M
J Exp Med; 2017 Sep; 214(9):2611-2628. PubMed ID: 28778989
[TBL] [Abstract][Full Text] [Related]
51. Impaired protein degradation in FTLD and related disorders.
Götzl JK; Lang CM; Haass C; Capell A
Ageing Res Rev; 2016 Dec; 32():122-139. PubMed ID: 27166223
[TBL] [Abstract][Full Text] [Related]
52. Prosaposin is a regulator of progranulin levels and oligomerization.
Nicholson AM; Finch NA; Almeida M; Perkerson RB; van Blitterswijk M; Wojtas A; Cenik B; Rotondo S; Inskeep V; Almasy L; Dyer T; Peralta J; Jun G; Wood AR; Frayling TM; Fuchsberger C; Fowler S; Teslovich TM; Manning AK; Kumar S; Curran J; Lehman D; Abecasis G; Duggirala R; Pottier C; Zahir HA; Crook JE; Karydas A; Mitic L; Sun Y; Dickson DW; Bu G; Herz J; Yu G; Miller BL; Ferguson S; Petersen RC; Graff-Radford N; Blangero J; Rademakers R
Nat Commun; 2016 Jun; 7():11992. PubMed ID: 27356620
[TBL] [Abstract][Full Text] [Related]
53. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia.
Amin S; Carling G; Gan L
Curr Opin Neurobiol; 2022 Feb; 72():131-139. PubMed ID: 34826653
[TBL] [Abstract][Full Text] [Related]
54. Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis.
Boland S; Swarup S; Ambaw YA; Malia PC; Richards RC; Fischer AW; Singh S; Aggarwal G; Spina S; Nana AL; Grinberg LT; Seeley WW; Surma MA; Klose C; Paulo JA; Nguyen AD; Harper JW; Walther TC; Farese RV
Nat Commun; 2022 Oct; 13(1):5924. PubMed ID: 36207292
[TBL] [Abstract][Full Text] [Related]
55. Increasing progranulin levels and blockade of the ERK1/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia.
Alquezar C; Esteras N; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
Eur Neuropsychopharmacol; 2015 Mar; 25(3):386-403. PubMed ID: 25624003
[TBL] [Abstract][Full Text] [Related]
56. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.
Logan T; Simon MJ; Rana A; Cherf GM; Srivastava A; Davis SS; Low RLY; Chiu CL; Fang M; Huang F; Bhalla A; Llapashtica C; Prorok R; Pizzo ME; Calvert MEK; Sun EW; Hsiao-Nakamoto J; Rajendra Y; Lexa KW; Srivastava DB; van Lengerich B; Wang J; Robles-Colmenares Y; Kim DJ; Duque J; Lenser M; Earr TK; Nguyen H; Chau R; Tsogtbaatar B; Ravi R; Skuja LL; Solanoy H; Rosen HJ; Boeve BF; Boxer AL; Heuer HW; Dennis MS; Kariolis MS; Monroe KM; Przybyla L; Sanchez PE; Meisner R; Diaz D; Henne KR; Watts RJ; Henry AG; Gunasekaran K; Astarita G; Suh JH; Lewcock JW; DeVos SL; Di Paolo G
Cell; 2021 Sep; 184(18):4651-4668.e25. PubMed ID: 34450028
[TBL] [Abstract][Full Text] [Related]
57. Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia.
Raitano S; Ordovàs L; De Muynck L; Guo W; Espuny-Camacho I; Geraerts M; Khurana S; Vanuytsel K; Tóth BI; Voets T; Vandenberghe R; Cathomen T; Van Den Bosch L; Vanderhaeghen P; Van Damme P; Verfaillie CM
Stem Cell Reports; 2015 Jan; 4(1):16-24. PubMed ID: 25556567
[TBL] [Abstract][Full Text] [Related]
58. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency.
Lee WC; Almeida S; Prudencio M; Caulfield TR; Zhang YJ; Tay WM; Bauer PO; Chew J; Sasaguri H; Jansen-West KR; Gendron TF; Stetler CT; Finch N; Mackenzie IR; Rademakers R; Gao FB; Petrucelli L
Hum Mol Genet; 2014 Mar; 23(6):1467-78. PubMed ID: 24163244
[TBL] [Abstract][Full Text] [Related]
59. Elevated levels of extracellular vesicles in progranulin-deficient mice and FTD-GRN Patients.
Arrant AE; Davis SE; Vollmer RM; Murchison CF; Mobley JA; Nana AL; Spina S; Grinberg LT; Karydas AM; Miller BL; Seeley WW; Roberson ED
Ann Clin Transl Neurol; 2020 Dec; 7(12):2433-2449. PubMed ID: 33197149
[TBL] [Abstract][Full Text] [Related]
60. Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias.
Meda F; Simrén J; Borroni B; Cantoni V; Archetti S; Biasiotto G; Andreasson U; Blennow K; Kvartsberg H; Zetterberg H
Clin Chem Lab Med; 2023 Nov; 61(12):2195-2204. PubMed ID: 37476993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
